Phenotyping [Design Issues]

posted by Essar – 2006-03-01 09:24 (6421 d 18:04 ago) – Posting: # 79
Views: 9,107

❝ If you plan a cross-over multiple dose study for such a drug, you may consider phenotyping in screening for safety reasons (i.e., include only FMs; otherwise you will end up in toxic range for the PMs). Example: paroxetine.

Dear Helmut,
Thanks for the clarification. Would need one more clarification:

Do we need to carry out Phenotyping for the single-dose, cross-over study also. We are planning to do the single-dose, cross-over BE study for Risperidone Tablets, and we have included phenotyping in this study. The justification provided by the concerned people is "to cancel out the inter-subject variability". But my question is that do we really require phenotyping in this study. Also, if inter-subject variability is a question, it will be taken care of by ANOVA. What do you suggest? Please enlighten.


Complete thread:

UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,627 registered users;
16 visitors (0 registered, 16 guests [including 8 identified bots]).
Forum time: 04:28 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz